Table 1. Characteristics and outcomes of... | American Society of Hematology

Table 1.

Characteristics and outcomes of selected autologous CD19-directed CAR T-cell trials for patients with B-ALL

Reference	Patient age (median; range) y	Number of patients	Previous lines of therapy (median; range)	Costimulatory domain	CR + CRi with MRD-negative remission, (%)	EFS/RFS/LFS	Grade ≥3 CRS, (%)	Grade ≥3 ICANS, (%)
Maude et al 2018¹⁰	11 (3-23)	75	3 (1-8)	4-1BB	81	50% EFS at 12 months	46	13
Shah NN et al 2021¹⁵	13.5 (4.3-30.4)	50	NA	CD28	62	38% EFS at 6 months	22	8
Myers et al 2021¹⁷ ∗	10.3 (1.7-29.1)	41	NA	4-1BB†	98	82% EFS at 12 months	15	7
Park et al 2018¹⁸	44 (23-64)	53	NA‡	CD28	83	Median EFS 6.1 months	26	42
Hay et al 2019¹⁹	39 (20-76)	53	3 (1-11)	4-1BB	85§	NA	19	23
Shah BD et al 2021²¹	40 (28-52)	55	2 (2-3)	CD28	71	58% RFS at 6 months	24	26
Rodie et al 2021²²	41.5 (18-62)	20	3 (2-6)	4-1BB	85§	44% EFS at 12 months	0	15
Zhang et al 2021²⁴	12 (2-61)	110	NA	4-1BB/CD28ε	87	58% LFS at 12 months	16	14ǁ

Reference	Patient age (median; range) y	Number of patients	Previous lines of therapy (median; range)	Costimulatory domain	CR + CRi with MRD-negative remission, (%)	EFS/RFS/LFS	Grade ≥3 CRS, (%)	Grade ≥3 ICANS, (%)
Maude et al 2018¹⁰	11 (3-23)	75	3 (1-8)	4-1BB	81	50% EFS at 12 months	46	13
Shah NN et al 2021¹⁵	13.5 (4.3-30.4)	50	NA	CD28	62	38% EFS at 6 months	22	8
Myers et al 2021¹⁷ ∗	10.3 (1.7-29.1)	41	NA	4-1BB†	98	82% EFS at 12 months	15	7
Park et al 2018¹⁸	44 (23-64)	53	NA‡	CD28	83	Median EFS 6.1 months	26	42
Hay et al 2019¹⁹	39 (20-76)	53	3 (1-11)	4-1BB	85§	NA	19	23
Shah BD et al 2021²¹	40 (28-52)	55	2 (2-3)	CD28	71	58% RFS at 6 months	24	26
Rodie et al 2021²²	41.5 (18-62)	20	3 (2-6)	4-1BB	85§	44% EFS at 12 months	0	15
Zhang et al 2021²⁴	12 (2-61)	110	NA	4-1BB/CD28ε	87	58% LFS at 12 months	16	14ǁ

NA, not available.

CAR T-cell–naive cohort.

With a humanized anti-CD19 single-chain variable fragment domain.

Previous therapies: 2, 40%; 3, 25%; and ≥4, 36%.

Rate of MRD-negative CR.

Grade 2-4 neurotoxicity.

Eighty-nine patients received 4-1BB construct; 21 patients received CD28 construct.